Professor Gareth Morgan from The Royal Marsden, UK, talks to ecancerTV about how far treatment in myeloma has come over the past decade. Also where it is likely to go in the coming years as the use of newer agents are fine-tuned to further improve outcomes. He focuses on new data from ASH 2012 such as maintenance treatment with lenalidomide and bortezomib, and notes how newer agents have considerably improved patients’ quality of life.
The challenge of whether to use single or combination agents remains, although Professor Morgan notes the additional challenge of toxicity in older patients with the use of combination agents. He points to the data on quadruplets of therapy presented at ASH 2012, and questions the use of this over triplets of therapy. Professor Morgan looks forward to the increased use of treatments according to laboratory sub-types, for example, using profiling to characterise mutational landscapes and sequencing to prevent the emergence of resistance in myeloma.